Gene modifiers in cystic fibrosis

Journal of Clinical Investigation

Volumn 118, Issue 3, 2008, Pages 839-841

  Accurso, Frank J ^a,b   Sontag, Marci K ^b,c  

^a Children's Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN 2; TRANSFORMING GROWTH FACTOR BETA1;

CYSTIC FIBROSIS; DNA MODIFICATION; ENTEROPATHY; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG DISEASE; NEWBORN SCREENING; NOTE; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SWEAT GLAND DISEASE;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MANNOSE-BINDING LECTIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 40549139451     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35138     Document Type: Note

References (17)

1. Kerem, B., et al. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science. 245:1073-1080.
2. Kerem, E., et al. 1990. The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (delta F508). N. Engl. J. Med. 323:1517-1522.
3. Kristidis, P., et al. 1992. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 50:1178-1184.
4. Vanscoy, L.L., et al. 2007. Heritability of lung disease severity in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175:1036-1043.
5. Blackman, S.M., et al. 2006. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology. 131:1030-1039.
6. Sontag, M.K., et al. 2006. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J. Pediatr. 149:650-657.
7. Drumm, M.L., et al. 2005. Genetic modifiers of lung disease in cystic fibrosis. N. Engl. J. Med. 353:1443-1453.
8. Buscher, R., and Grasemann, H. 2006. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road? Naunyn. Schmiedebergs Arch. Pharmacol. 374:65-77.
9. Dorfman, R., et al. 2008. Complex two-gene modulation of lung disease severity in children with cys tic fibrosis. J. Clin. Invest. 118:1040-1049.
10. Garred, P., et al. 1999. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J. Clin. Invest. 104:431-437.
11. Konstan, M.W., et al. 2007. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J. Pediatr. 151:134-139.
12. Frederiksen, B., Koch, C., and Hoiby, N. 1997. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23:330-335.
13. Rowe, S.M., Accurso, F., and Clancy, J.P. 2007. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc. Am. Thorac. Soc. 4:387-398.
14. Buranawuti, K., et al. 2006. Variants in mannose-binding lectin and tumor necrosis factor {alpha} affect survival in cystic fibrosis. J. Med. Genet. 44:209-214.
15. Harradine, K.A., and Akhurst, R.J. 2006. Mutations of TGFbeta signaling molecules in human disease. Ann. Med. 38:403-414.
16. Mayer-Hamblett, N., Ramsey, B.W., and Kronmal, R.A. 2007. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc. Am. Thorac. Soc. 4:370-377.
17. Farrell, P.M., et al. 2001. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics. 107:1-13.